Effect of Medicine on Interleukin-6 Inhibitors and their Forms Against COVID-19

KUŞAT K., AKGÖL S.

Biointerface Research in Applied Chemistry, cilt.12, 2021 (ESCI) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 12
  • Basım Tarihi: 2021
  • Doi Numarası: 10.33263/briac121.756767
  • Dergi Adı: Biointerface Research in Applied Chemistry
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Anahtar Kelimeler: COVID-19, interleukin-6, IL-6/JAK/STAT3 signal pathway inhibitors, nanomedicine, nanotechnology, theranostic strategies
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), previously known as the 2019 novel coronavirus (2019-nCoV). The first cases were seen in December 2019 in Wuhan. To date, there is no specific treatment for COVID-19 disease. Recent clinical trials suggest that interleukin-6 (IL-6) inhibitors and their derivates could play a role as a therapeutic agent against COVID-19. It is prominent to assess potential therapeutic effects of drugs that are clinically approved for other indications. In addition, IL-6 inhibitors have been used in nanomedicine. This review focuses on the development of nanosystems for the therapy of COVID-19. IL-6 inhibitors and signal pathway inhibitors attached to biocompatible nanomaterials may provide a useful route for the treatment of COVID-19. This review would also help scientists who make potential drug research via attachment of interleukin-6 inhibitors and their derived forms to biocompatible nanomaterials for treatment of COVID-19.